BioCryst Pharmaceuticals to Present New Pediatric HAE Data
BioCryst Pharmaceuticals, Inc. (NASDAQ: BCRX) is gearing up for a significant presentation at the Annual Scientific Meeting of the American College of Allergy, Asthma & Immunology (ACAAI). The event will happen in Orlando, with a schedule packed full of crucial insights and new findings.
Key Presentations on Pediatric Patients
The company will unveil four pivotal abstracts highlighting their ongoing commitment to researching and improving care for pediatric patients suffering from hereditary angioedema (HAE). One of the key presentations will showcase the second interim analysis of the APeX-P trial, which looks at long-term prophylaxis using an innovative oral granule formulation of ORLADEYO (berotralstat) for children ages 2 to under 12. This research not only examines efficacy but also delves into the psychosocial impacts of HAE on young patients and their families.
Details of the Presentations
Here’s a brief overview of the poster presentations BioCryst will showcase:
- Hereditary Angioedema Attack Rates in Children 2-12 with Oral Prophylactic Berotralstat Over One Year; ePoster #R089; available on November 7, from 2:50-3:05 p.m. ET.
- Psychosocial Impact of Hereditary Angioedema on Young Patients and Their Caregivers; ePoster #R102; presented on November 7, from 2:50-3:05 p.m. ET.
- Burden of Attack for Young Patients with Hereditary Angioedema and Their Caregivers; ePoster #R109; on November 8, from 11:30-11:45 a.m. ET.
- Emergency Department Experiences of Young Patients with Hereditary Angioedema and Their Caregivers; ePoster #R117; shown on November 9, from 12:00-12:15 p.m. ET.
These presentations will undoubtedly provide valuable insights into the management and treatment of HAE in pediatric patients that can inform both clinical practice and future research efforts.
Accessibility of ePosters
In a move to enhance accessibility, BioCryst will ensure that these ePosters are available online and on demand for registered attendees starting November 6, 2025. This initiative broadens the reach of their findings beyond the physical attendees at the conference.
Understanding ORLADEYO (berotralstat)
ORLADEYO (berotralstat) is a groundbreaking oral therapy, specifically designed for preventing HAE attacks in both adults and pediatric patients 12 years and older. This revolutionary treatment offers a once-daily capsule that effectively lowers plasma kallikrein activity, thus helping to prevent attack occurrences.
Though it is a significant therapeutic advancement, it’s key to note limited indications. It is crucial for patients and caregivers to understand that ORLADEYO is not intended for the treatment of acute HAE attacks. Furthermore, any changes in dosage must be carefully monitored due to the possibility of QT prolongation, highlighting the importance of adhering to prescribed guidelines.
Safety and Side Effects Overview
While ORLADEYO has shown promise, common side effects reported in patients include abdominal pain, vomiting, and diarrhea. Careful consideration must be given while prescribing this treatment, particularly in patients with moderate to severe hepatic impairment, requiring a tailored approach to ensure efficacy and safety.
BioCryst Pharmaceuticals: Leading the Way in Rare Diseases
BioCryst Pharmaceuticals is on a mission to revolutionize treatment for hereditary angioedema and other rare diseases. With a robust pipeline focused on developing innovative therapies, the company harnesses the power of structure-guided drug design. This dedication illustrates their commitment to not just creating treatments but also improving the overall quality of life for patients and families affected by challenging health conditions.
For further information on BioCryst Pharmaceuticals and their initiatives, connect with them through their official website or follow their updates on LinkedIn.
Frequently Asked Questions
What types of data will BioCryst present at the ACAAI meeting?
BioCryst will present data on the prophylactic treatment of hereditary angioedema in pediatric patients, including findings from the APeX-P trial.
Where can I access the ePosters?
The ePosters will be available online for registered attendees on November 6, providing a wider audience the chance to view the research.
What is ORLADEYO and who is it intended for?
ORLADEYO (berotralstat) is an oral therapy designed to prevent attacks of hereditary angioedema in patients aged 12 and older, notable for its once-daily convenience.
Are there any safety concerns associated with ORLADEYO?
Yes, ORLADEYO can have side effects such as abdominal pain and may pose risks for QT prolongation, requiring careful monitoring of patients.
How committed is BioCryst to patients with rare diseases?
BioCryst is dedicated to improving the lives of those with rare diseases through innovative research, development, and compassionate patient care practices.
